

PRESS RELEASE

Gradientech announces outcome of rights issue

Uppsala, Sweden, September 04, 2026. **The diagnostics company Gradientech AB (publ) ("Gradientech" or the "Company") today announces the outcome of the new issue of shares with preferential rights for existing shareholders (the "Rights Issue") resolved by the Board of Directors on August 06, 2026. The final count in the Rights Issue shows that 5,419,001 shares, corresponding to approximately 86 percent of the Rights Issue were subscribed for. Through the Rights Issue, Gradientech will receive approximately SEK 47.4 million before deductions for issue costs.**

The subscription period for the Rights Issue expired on August 31, 2026. The final outcome shows that 3,686,573 shares, corresponding to approximately 68 percent of the Rights Issue, were subscribed for with subscription rights and 1,732,428 shares, corresponding to approximately 32 percent of the Rights Issue, without subscription rights. Through the Rights Issue, the Company's share capital will increase by SEK 541,900.10 to SEK 4,336,936.00 and the number of shares will increase by 5,419,001 shares to 43,369,360 shares.

Approximately one week after the Rights Issue has been registered with the Swedish Companies Registration Office, which is expected to take place in September, BTA will be converted into shares. Notification of allotment for shares signed up for without subscription rights, will be made by means of a settlement note to each subscriber. Allocated shares shall be paid in accordance with the instructions on the settlement note.

No compensation is paid for submitted subscription commitments. Aqurat Fondkommission AB is acting as issuing agent and Advokatfirman Lindahl KB is acting as legal advisor to Gradientech in connection with the issue.

For further information, please contact:

Sumi Thaker, CEO

sumi.thaker@gradientech.se

Urban Adolfsson, CFO

Phone: + 46 708 20 72 09

urban.adolfsson@gradientech.se

About Gradientech

Gradientech develops next-generation diagnostics for infectious disease medicine. Its QuickMIC[®] system provides ultra-rapid antibiotic susceptibility testing to help clinicians identify the most effective antibiotic treatment faster. By shortening the time to an informed treatment decision, Gradientech aims to improve patient outcomes, reduce health care costs and support the global effort against antibiotic resistance — one of the greatest threats to public health. Gradientech is headquartered in Uppsala, Sweden. Visit gradientech.se for more information.